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Pandemic (H1N1) 
2009 and 
Oseltamivir 
Resistance in 
Hematology/
Oncology Patients
To the Editor: Tramontana et 
al. (1) recently described character-
istics and oseltamivir resistance in 
hematology and oncology patients 
infected with pandemic (H1N1) 2009 
virus. Such cases merit further study 
because concurrent medical prob-
lems in immunosuppressed patients 
may obscure and delay diagnosis and 
management of pandemic (H1N1) 
2009 infections. Moreover, severe 
complications of such infection may 
be more likely to develop in immu-
nosuppressed patients (2). During the 
winter of 2009, oseltamivir-resistant 
pandemic (H1N1) 2009 virus infec-
tion was diagnosed for 4 patients at 
Duke University Medical Center. We 
describe the clinical features of the 
infections, the challenges associated 
with diagnosis of pandemic (H1N1) 
2009 virus infection, and the clinical 
outcome for the infected patients.
Four immunocompromised pa-
tients who received chemotherapy and 
immunotherapy for solid-organ and 
hematologic malignancies were hospi-
talized at our tertiary care medical cen-
ter during October–November 2009, a 
period of peak activity of pandemic 
(H1N1) 2009 in surrounding commu-
nities in North Carolina (3). These 4 
case-patients experienced symptoms 
attributable to pandemic (H1N1) 2009 
from 0 to 14 days after hospital admis-
sion, and the diagnosis of pandemic 
(H1N1) 2009 was made 0–28 days af-
ter symptom onset. Illness, diagnosis, 
and treatment of the patients are sum-
marized in the Table. One patient re-
ported contact with a family member 
who had inﬂ  uenza-like illness. Three 
other patients likely acquired pandem-
ic (H1N1) 2009 in the hospital. An 
investigation could not conclusively 
establish whether transmission of pan-
demic (H1N1) 2009 occurred between 
case-patients and healthcare workers 
or visitors (4). All 4 case-patients ulti-
mately died; 2 patients recovered from 
pandemic (H1N1) 2009 after antiviral 
drug therapy but died of underlying 
disease and subsequent bacterial infec-
tions. One case-patient did not receive 
antiviral drugs because the diagnosis 
was made posthumously.
We learned valuable lessons re-
garding diagnosis and management of 
pandemic (H1N1) 2009 in immuno-
compromised patients. First, pandemic 
(H1N1) 2009 infection can be difﬁ  cult 
to diagnose in immunocompromised 
hospitalized patients. Such patients 
do not exhibit consistent symptoms 
or signs for pandemic (H1N1) 2009. 
Consistent with Tramontana et al. (1), 
fever was the most common feature, 
followed by progressive dyspnea and 
intermittent cough. None of our pa-
tients reported sore throat. Moreover, 
such nonspeciﬁ   c symptoms may be 
inadvertently attributed to concurrent 
medical problems common in immu-
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nocompromised patients such as bone 
marrow suppression, adverse effects of 
drugs or chemotherapy, recent surgical 
procedures, opportunistic infections, 
or line-related bloodstream infections.
Second, respiratory viruses may 
be imported and subsequently trans-
mitted to hospitalized patients despite 
standard infection prevention mea-
sures (5). Clinicians should remain 
vigilant for hospital-onset respiratory 
viral infections and have a low thresh-
old for diagnostic testing, particularly 
during periods of increased inﬂ  uenza 
or respiratory virus activity in the 
community.
Early suspicion and prompt test-
ing may have reduced the delay in 
the diagnosis and management of 
these patients with pandemic (H1N1) 
2009. However, the initial nasal wash 
specimen from patient 1 was nega-
tive for pandemic (H1N1) 2009 virus 
antigen, whereas the initial bronchos-
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Table. Clinical, diagnostic, and therapeutic patient information for 4 patients hospitalized for hematologic and oncologic conditions, 
North Carolina, USA, 2009* 
Patient information 
Patient no./age, y/sex 
1/43/F 2/58/F  3/67/F  4/61/M 
Underlying disease  Relapsed acute 
myelogenous leukemia 
Refractory mycosis 
fungoides 
Recurrent metastatic 
thymoma 
B-cell acute lyphoblastic 
lymphoma 
Reason for admission  Scheduled consolidative 
chemotherapy 
Staphylococcal sepsis; 
recent interferon-Į; 
malnutrition 
Progressive fevers and 
hypoxia; diffuse; 
infiltrates shown on 
chest radiograph 
Fevers and respiratory 
compromise at home, 
after recent 
chemotherapy 
Signs/symptoms on 
admission 
Intermittent fever during 
early admission; d 14† 
cough, persistent fevers; d 
24 progressive hypoxia 
Intermittent fevers; d 27, 
cough; persistent fevers, 
progressive hypoxia 
Fever for 5 d; hypoxia, 
widespread pulmonary 
infiltrates 
Daily fevers for 5 d, 
cough, hypoxia, fatigue, 
generalized weakness; 
diffuse infiltrates on 
radiograph 
Use of oseltamivir  Yes, for 10 d; 75 mg daily 
prophylaxis after known 
exposure 2 d prior 
No No  No 
Diagnostic information  d 14, nasal wash PCR 
negative‡; d 25, BAL 
positive for pandemic 
(H1N1) 2009 virus; d 37, 
BAL remained positive, 
H275Y mutation
 
d 27 nasal wash positive 
for pandemic (H1N1) 2009 
virus; d 44, H275Y 
mutation confirmed on d 
27 specimen; medication 
modified 
d 1, nasal wash 
positive for pandemic 
(H1N1) 2009 virus; d 4, 
d 9, bronchoscopy 
results positive; d 12, 
bronchoscopy results 
negative for influenza 
on culture and PCR; 
H275Y mutation 
detected on all positive 
specimens§ 
d 23 bronchoscopy and 
d 27 nasal wash results 
negative; d 28 
bronchoscopic viral 
culture positive for 
pandemic (H1N1) 2009 
virus, 1 d after patient’s 
death; H275Y mutation 
detected by CDC 
Factors confounding 
pandemic (H1N1) 
2009 diagnosis 
Consolidation 
chemotherapy; Escherichia 
coli bacteremia, 
presumptive fungal 
pneumonia, persistent 
leukopenia neutropenia 
postchemotherapy 
Staphylococcus aureus, 
Pseudomonas aeruginosa, 
Klebsiella  pneumoniae 
bacteremia; recent 
interferon-Į therapy; 
salvage chemotherapy; 
persistent leukopenia and 
neutropenia at discharge 
Recent thoracic 
radiotherapy; catheter-
associated 
Staphylococcus aureus 
bloodstream infection. 
Consolidative 
chemotherapy with 
prolonged neutropenia; 
significant emphysema; 
catheter-associated 
pseudomonal 
bloodstream infection 
Treatment  Oseltamivir,75 mg 2u/d for 
5 d; then, 150 mg 2u/d until 
death; mechanical 
ventilation for 15 d 
Oseltamivir, 75 mg 2u/d for 
9 d; then 150 mg 2u/d for 8 
d; modified to renally 
adjusted IV zanamivir for 
10 d, when mutation 
detected 
Oseltamivir, 75 mg 
2u/d for 12 d; 
mechanical ventilation 
for 16 d 
Broad-spectrum 
antibacterial agents; 
antiviral agents (not 
influenza agents), and 
antifungal agents; 
mechanical ventilation for 
48 h 
Clinical outcome  Died 38 d postadmission; 
refractory respiratory failure 
and progressive ARDS 
Improvement in respiratory 
status following zanamivir 
treatment; ultimately, 
failure of bone marrow 
recovery; died 4 d after 
discharge to hospice 
Refractory respiratory 
failure; septic shock; 
decision to withdraw 
care 
Refractory respiratory 
failure and elective 
withdrawal of care 
*BAL, bronchoalveolar lavage; ARDS, acute respiratory disease syndrome;  IV, intravenous; CDC, Centers for Disease Control and Prevention. 
†Days postadmission. 
‡All specimens, unless otherwise stated, were tested with proFlu Plus PCR (Prodesse, Waukesha, WI, USA) for influenza viruses A and B and respiratory 
syncytial virus. No quantitative tests were available. 
§Mutation genotype confirmed at CDC. Results were available posthumously for patients 1, 3, and 4. No mutation that conferred zanamivir resistance 
was detected. LETTERS
copy and nasal wash specimens from 
patient 4 also were negative for such 
antigens on laboratory testing. This 
underscores the limitations of current 
testing and that the sensitivity of pan-
demic (H1N1) 2009 diagnostic test-
ing remains poor and needs further 
improvement. Thus, in patients sus-
pected of having pandemic (H1N1) 
2009 or in those who are critically 
ill, lower tract respiratory specimens 
should tested to improve diagnostic 
sensitivity, and clinicians should con-
sider using immunoassay and culture 
methods.
All 4 patients described in this 
case series had viral isolates contain-
ing H275Y mutation in the neuramini-
dase gene of pandemic (H1N1) 2009 
virus, which is speciﬁ  cally associated 
with high-level resistance to oseltami-
vir. Increasing data show that immuno-
compromised patients are at increased 
risk for development of drug-resistant 
inﬂ  uenza infections after oseltamivir 
prophylaxis or while receiving osel-
tamivir treatment (6). Fortunately, this 
resistance trait remains rare.
Existing evidence suggests os-
eltamivir-resistant pandemic (H1N1) 
2009 virus is stable and retains simi-
lar transmissibility and virulence as 
the wild-type virus (7). Therefore, 
in immunosuppressed patients, in 
which the inﬂ  uenza mortality rate is 
high, clinicians should also suspect 
drug-resistant inﬂ   uenza infection if 
the patient does not improve. Before 
she died of underlying hematologic 
illness, patient 2 clinically improved 
after treatment with intravenous 
zanamivir (obtained through an 
emergency application for an inves-
tigational–new drug). As reported in 
other studies, pandemic (H1N1) 2009 
virus was found in her nasal washes, 
1 week after she received zanamivir 
for 10 days (8).
Some data suggest that pandemic 
(H1N1) 2009 virus has a predilection 
to affect the lower respiratory tract 
and is associated with more illness 
and death than is seasonal inﬂ  uenza 
(9). All 4 case-patients with in this se-
ries developed dyspnea, and 3 of the 
4 ultimately died of refractory respira-
tory failure. Our observations suggest 
that oseltamivir-resistant pandemic 
(H1N1) 2009 virus is also associated 
with poor prognosis and may retain 
the same tropism for lower respiratory 
tract involvement as wild type.
These case-patients illustrated the 
complexity of the diagnosis and man-
agement of such infections in hospi-
talized immunocompromised patients. 
Vigilance and heightened clinical sus-
picion are needed to facilitate early 
diagnosis, treatment and prevention 
measures to limit transmission of pan-
demic (H1N1) 2009 virus or similar 
viral pathogens.
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Acute 
Encephalopathy 
and Pandemic 
(H1N1) 2009 
To the Editor: Since the World 
Health Organization declared a global 
pandemic of inﬂ  uenza  A  pandemic 
(H1N1) 2009 in June 2009, the num-
ber of cases of this strain of inﬂ  uenza 
has steadily risen. Although most cas-
es have been mild, with complete and 
uneventful recovery, multiple cases of 
severe infection with complications, 
including death, have been reported. 
Yet the neurologic complications of 
this virus have been rarely described. 
We read with interest the article by 
Kitcharoen et al. (1) concerning a pa-
tient with encephalopathy associated 
with pandemic (H1N1) 2009, which 
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